Tango Therapeutics (TNGX) Cash from Operations (2020 - 2026)

Tango Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 44360000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 6.39% year-over-year to 44360000.0 in Q1 2026; TTM through Mar 2026 was 141549000.0, a 4.59% decrease from a year earlier, with the FY2025 full-year figure at 138886000.0, down 5.62% from the prior year.
• Cash from Operations eased to 44360000.0 in Q1 2026 per TNGX's latest filing, from 29718000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 19611000.0 in Q3 2022 and bottomed at 44360000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 31135000.0 (2023), against an average of 31871117.65.
• Across the five-year window, Cash from Operations tumbled 319.5% in 2022 and climbed 22.4% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 28266000.0 in 2022, then gained by 2.83% to 27467000.0 in 2023, then slumped by 33.42% to 36647000.0 in 2024, then climbed by 18.91% to 29718000.0 in 2025, then plunged by 49.27% to 44360000.0 in 2026.
• Per Business Quant, the three latest TNGX Cash from Operations figures stand at 44360000.0 (Q1 2026), 29718000.0 (Q4 2025), and 30952000.0 (Q3 2025).